Trials / Recruiting
RecruitingNCT06639347
A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma
An Open Label, Multicenter, Phase Ib/Il Study to Evaluate the Safety, Tolerability, and Efficacy of SHR A2102 in Combination With Other Anti-cancer Agents in Patients With Advanced Urothelial Carcinoma
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 for injection with Antitumor Therapy in Advanced Urothelial Carcinoma. To explore the reasonable dosage of SHR-A2102 for Advanced Urothelial Carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-A2102 | SHR-A2102 |
| DRUG | Adebrelimab injection | Adebrelimab injection |
| DRUG | SHR-8068 injection | SHR-8068 injection |
Timeline
- Start date
- 2024-11-04
- Primary completion
- 2027-05-31
- Completion
- 2027-05-31
- First posted
- 2024-10-15
- Last updated
- 2024-11-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06639347. Inclusion in this directory is not an endorsement.